Testing Neuroaid II for mild to moderate Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests an investigational drug called Neuroaid II (MLC901) for people with mild to moderate Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older.
- You have a diagnosis of Alzheimer's disease confirmed by a blood test (elevated ptau217).
- Your memory and thinking test (MMSE) score is between 10 and 26, which means mild to moderate Alzheimer's.
- You have a study partner (like a family member or friend) who spends at least 8 hours with you weekly and can come to visits or be available by phone.
- You are not currently taking any Alzheimer's disease-modifying therapies or certain supplements (like Ginkgo biloba or Piracetam).
- You do not have other neurological conditions (like Parkinson's, stroke, seizures) or serious medical illnesses that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, QLH2405, for people with mild cognitive impairment or mild Alzheimer's disease. It aims to see if the drug is safe and how it affects memory and thinking.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
This early-stage trial tests how safe and well-tolerated a new drug called 8M2D is in healthy volunteers and people with early Alzheimer's disease. Researchers want to understand how the body handles the drug and whether it might help slow memory loss.
Hear when a new Alzheimer's Disease Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.